Published by PM360 – August 9, 2017

The growing power of payers in healthcare decision-making has put an increased emphasis on health economics and outcomes research (HEOR), as the data collected through that research is key to demonstrating the value of your drug. As HEOR teams have grown in importance, their roles have expanded to be included in nearly every facet of drug development to ensure the right information is being collected. Furthermore, a report published by PharmaForce International earlier this year revealed that pharma companies increased their field-based HEOR personnel by 53% in 2016. So basically, any pharma company that hasn’t upped their HEOR game yet should strongly consider it. To help you, PM360 asked several experts in this field, including OM1’s CEO Richard Gliklich. Read more.